1. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway
- Author
-
Hu Jinping, Qin Zhou, Yan Li, Chao Li, Ming Ji, Xiaoguang Chen, Nina Xue, Ju Chen, Haining Lv, Shuang-Gang Ma, Shi-Shan Yu, and Bin Lin
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Cell ,Administration, Oral ,Pharmacology ,0302 clinical medicine ,Prodrugs ,Mice, Inbred BALB C ,Mice, Inbred ICR ,Indolizidines ,biology ,Smoothened Receptor ,Hedgehog signaling pathway ,Tumor Burden ,Patched-1 Receptor ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Female ,Signal Transduction ,Mice, Nude ,Repressor ,Antineoplastic Agents ,Zinc Finger Protein GLI1 ,Inhibitory Concentration 50 ,03 medical and health sciences ,GLI1 ,Cell Line, Tumor ,medicine ,Animals ,Hedgehog Proteins ,Cerebellar Neoplasms ,Hedgehog ,Cell Proliferation ,Medulloblastoma ,Dose-Response Relationship, Drug ,Phenanthrenes ,medicine.disease ,Cyclic AMP-Dependent Protein Kinases ,Xenograft Model Antitumor Assays ,Repressor Proteins ,030104 developmental biology ,PTCH1 ,Drug Design ,Cancer research ,biology.protein ,Glioblastoma ,Smoothened - Abstract
Medulloblastoma (MB) and glioblastoma (GBM) are the most prevalent malignant brain tumors. The identification of novel therapeutic strategies is urgent for MB and GBM patients. Herein, we discovered 13a-(S)-3-Hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine (PF403) strongly exhibited inhibitory activity against Hedgehog (Hh) pathway-hyperactivated MB and GBM cells with a 50% inhibitory concentration (IC50) of 0.01 nM. CAT3 was designed and synthesized as the prodrug of PF403 and displayed significant in vivo efficacy against MB and GBM. Mechanistic study revealed that CAT3 inhibited MB and GBM primarily by interrupting the Hh signaling pathway. At the molecular level, PF403 inhibited the cell surface accumulation of the Smoothened (Smo) receptor by directly binding or enhancing the interaction of Smo with the repressor Ptch1. Furthermore, PF403 significantly repressed Gli1 nuclear accumulation and transcription by promoting Sufu-Gli1 and PKA-Gli1 interactions. Collectively, our studies support the hypothesis that CAT3 is a promising therapeutic agent for the treatment of Hh-driven MB and GBM.
- Published
- 2016
- Full Text
- View/download PDF